Zavegepant Nasal Spray: Year-Long Relief for Migraine Sufferers

Research Summary

A recent study published in Pain Therapy explores the impact of zavegepant nasal spray on migraines over a 52-week period. Conducted as an open-label study, 603 participants used the 10 mg nasal spray as needed, revealing significant findings. Zavegepant reduced migraine days by an average of 1.7 days for any pain intensity and 1.1 days for moderate to severe pain each month. Improvements were noted in migraine-related disability and quality of life, with a -8.2 reduction in MIDAS scores at week 12 and -8.8 at week 52. By the study's end, 44% of participants were highly satisfied with the treatment.

Study Details

📄 Title: Patient-Reported Outcomes During the Acute Treatment of Migraine with Zavegepant Nasal Spray: Results from a 52-Week, Open-Label Study.

👥 Research Team: Lipton RB, Mosher L, Fountaine RJ

📚 Published In: Pain Ther

📅 Publication Date: 2025 Dec 11

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.